Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.55 |
| ▸ | FNTB | P49356 | 7/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182638 | 0.89 | FNTA (0.55) | FNTAFNTBHSD17B10KMT2ACNR1 | |
| SCHEMBL6169572 | 0.81 | FNTA (0.53) | FNTAFNTB | |
| SCHEMBL6010160 | 0.78 | FNTA (0.78) | FNTAFNTB | |
| SCHEMBL5550230 | 0.77 | FNTA (0.47) | FNTAFNTBHSD17B10KMT2A | |
| SCHEMBL27251471 | 0.77 | FNTA (0.66) | FNTAFNTBHSD17B10CNR1 | |
| SCHEMBL14588476 | 0.76 | FNTA (0.64) | FNTAFNTBHSD17B10KMT2A | |
| SCHEMBL8171779 | 0.76 | FNTA (0.55) | FNTAFNTBHSD17B10 | |
| SCHEMBL12590521 | 0.74 | FNTA (0.63) | FNTAFNTB | |
| SCHEMBL14588475 | 0.74 | FNTA (0.62) | FNTAFNTBHSD17B10CNR1 | |
| SCHEMBL6010441 | 0.73 | FNTA (0.57) | FNTAFNTBHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150973-B1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6710209-B2 | INHIBITING FARNESYL PROTEIN TRANSFERASE. | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| US-6388092-B2 | ANTITUMOR AGENT | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | FNTA 855/4885FNTB 2166/4885HSD17B10 2359/4885 |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | FNTA 855/4885FNTB 2166/4885HSD17B10 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.